Loading…
Ciprofloxacin as Therapy for Experimental Osteomyelitis Caused by Pseudomonas aeruginosa
Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. Treatment with tobramycin for four weeks was ineffective (94% had positive bone cultures). In contrast, ciprofloxacin administer...
Saved in:
Published in: | The Journal of infectious diseases 1985-02, Vol.151 (2), p.291-294 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c346t-812119984712bbcc1d75ad44cc88e0a7574cc9f269988edf4b0e2c357ba156f43 |
---|---|
cites | |
container_end_page | 294 |
container_issue | 2 |
container_start_page | 291 |
container_title | The Journal of infectious diseases |
container_volume | 151 |
creator | Norden, Carl W. Shinners, Ellen |
description | Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. Treatment with tobramycin for four weeks was ineffective (94% had positive bone cultures). In contrast, ciprofloxacin administered for four weeks sterilized the bones of all but one (94%) of 18 treated rabbits. Treatment with ciprofloxacin for two weeks was less effective than treatment for four weeks but was more effective than either treatment with tobramycin or no therapy. Two of 10 isolates from rabbits treated with ciprofloxacin for two weeks were susceptible to MICs of ciprofloxacin that were 16- and fourfold greater than the MIC for the parent strain; the other eight isolates remained sensitive to ciprofloxacin with MICs equivalent to that of the parent strain. |
doi_str_mv | 10.1093/infdis/151.2.291 |
format | article |
fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_75954345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>30109785</jstor_id><sourcerecordid>30109785</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-812119984712bbcc1d75ad44cc88e0a7574cc9f269988edf4b0e2c357ba156f43</originalsourceid><addsrcrecordid>eNqFkctr3DAQh0VoSLdp7r0UfCi9eaOnJR3LkjSFQEoebehFjGWpUWJbW8mG3f--CrtNjj2N4PcY5hNCHwheEqzZaRh9F_IpEWRJl1STA7Qggsm6aQh7gxYYU1oTpfVb9C7nR4wxZ408QkeMCCEVXqD7VVin6Pu4ARvGCnJ1--ASrLeVj6k626xdCoMbJ-irqzy5OGxdH6aQqxXM2XVVu62-Zzd3cYhjCYNL8-8wxgzv0aGHPruT_TxGd-dnt6uL-vLq67fVl8vaMt5MtSKUEK0Vl4S2rbWkkwI6zq1VymGQQpan9rQpHuU6z1vsqGVCtkBE4zk7Rp93veWMP7PLkxlCtq7vYXRxzkYKLTjj4r9GwrESmulixDujTTHn5LxZFwaQtoZg80zd7KibQt1QU6iXyMd999wOrnsJ7DEX_dNeh2yh9wlGWwr-2RTHVFL2WvOYp5heW3DZKtXzCfVOD-UrNi86pCfTSCaFubj_Zej59U-qb34Yxv4Ca82lOg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>14085939</pqid></control><display><type>article</type><title>Ciprofloxacin as Therapy for Experimental Osteomyelitis Caused by Pseudomonas aeruginosa</title><source>JSTOR Archival Journals and Primary Sources Collection</source><source>Oxford University Press Archive</source><creator>Norden, Carl W. ; Shinners, Ellen</creator><creatorcontrib>Norden, Carl W. ; Shinners, Ellen</creatorcontrib><description>Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. Treatment with tobramycin for four weeks was ineffective (94% had positive bone cultures). In contrast, ciprofloxacin administered for four weeks sterilized the bones of all but one (94%) of 18 treated rabbits. Treatment with ciprofloxacin for two weeks was less effective than treatment for four weeks but was more effective than either treatment with tobramycin or no therapy. Two of 10 isolates from rabbits treated with ciprofloxacin for two weeks were susceptible to MICs of ciprofloxacin that were 16- and fourfold greater than the MIC for the parent strain; the other eight isolates remained sensitive to ciprofloxacin with MICs equivalent to that of the parent strain.</description><identifier>ISSN: 0022-1899</identifier><identifier>EISSN: 1537-6613</identifier><identifier>DOI: 10.1093/infdis/151.2.291</identifier><identifier>PMID: 3155780</identifier><identifier>CODEN: JIDIAQ</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Animals ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobials ; Biological and medical sciences ; Body weight ; Bone and Bones - analysis ; Bones ; Chronic Disease ; Ciprofloxacin ; Drug Resistance, Microbial ; Injections ; Inoculum ; Medical sciences ; Medical treatment ; Original Articles ; Osteomyelitis ; Osteomyelitis - drug therapy ; Osteomyelitis - etiology ; Osteomyelitis - microbiology ; Pharmacology. Drug treatments ; Pseudomonas aeruginosa ; Pseudomonas aeruginosa - drug effects ; Pseudomonas Infections - drug therapy ; Pseudomonas Infections - microbiology ; Quinolines - analysis ; Quinolines - blood ; Quinolines - pharmacology ; Quinolines - therapeutic use ; Rabbits ; Sterilization ; Tobramycin - therapeutic use</subject><ispartof>The Journal of infectious diseases, 1985-02, Vol.151 (2), p.291-294</ispartof><rights>Copyright 1985 The University of Chicago</rights><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-812119984712bbcc1d75ad44cc88e0a7574cc9f269988edf4b0e2c357ba156f43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/30109785$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/30109785$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,58238,58471</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8402723$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3155780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Norden, Carl W.</creatorcontrib><creatorcontrib>Shinners, Ellen</creatorcontrib><title>Ciprofloxacin as Therapy for Experimental Osteomyelitis Caused by Pseudomonas aeruginosa</title><title>The Journal of infectious diseases</title><addtitle>J Infect Dis</addtitle><description>Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. Treatment with tobramycin for four weeks was ineffective (94% had positive bone cultures). In contrast, ciprofloxacin administered for four weeks sterilized the bones of all but one (94%) of 18 treated rabbits. Treatment with ciprofloxacin for two weeks was less effective than treatment for four weeks but was more effective than either treatment with tobramycin or no therapy. Two of 10 isolates from rabbits treated with ciprofloxacin for two weeks were susceptible to MICs of ciprofloxacin that were 16- and fourfold greater than the MIC for the parent strain; the other eight isolates remained sensitive to ciprofloxacin with MICs equivalent to that of the parent strain.</description><subject>Animals</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobials</subject><subject>Biological and medical sciences</subject><subject>Body weight</subject><subject>Bone and Bones - analysis</subject><subject>Bones</subject><subject>Chronic Disease</subject><subject>Ciprofloxacin</subject><subject>Drug Resistance, Microbial</subject><subject>Injections</subject><subject>Inoculum</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Original Articles</subject><subject>Osteomyelitis</subject><subject>Osteomyelitis - drug therapy</subject><subject>Osteomyelitis - etiology</subject><subject>Osteomyelitis - microbiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pseudomonas aeruginosa</subject><subject>Pseudomonas aeruginosa - drug effects</subject><subject>Pseudomonas Infections - drug therapy</subject><subject>Pseudomonas Infections - microbiology</subject><subject>Quinolines - analysis</subject><subject>Quinolines - blood</subject><subject>Quinolines - pharmacology</subject><subject>Quinolines - therapeutic use</subject><subject>Rabbits</subject><subject>Sterilization</subject><subject>Tobramycin - therapeutic use</subject><issn>0022-1899</issn><issn>1537-6613</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><recordid>eNqFkctr3DAQh0VoSLdp7r0UfCi9eaOnJR3LkjSFQEoebehFjGWpUWJbW8mG3f--CrtNjj2N4PcY5hNCHwheEqzZaRh9F_IpEWRJl1STA7Qggsm6aQh7gxYYU1oTpfVb9C7nR4wxZ408QkeMCCEVXqD7VVin6Pu4ARvGCnJ1--ASrLeVj6k626xdCoMbJ-irqzy5OGxdH6aQqxXM2XVVu62-Zzd3cYhjCYNL8-8wxgzv0aGHPruT_TxGd-dnt6uL-vLq67fVl8vaMt5MtSKUEK0Vl4S2rbWkkwI6zq1VymGQQpan9rQpHuU6z1vsqGVCtkBE4zk7Rp93veWMP7PLkxlCtq7vYXRxzkYKLTjj4r9GwrESmulixDujTTHn5LxZFwaQtoZg80zd7KibQt1QU6iXyMd999wOrnsJ7DEX_dNeh2yh9wlGWwr-2RTHVFL2WvOYp5heW3DZKtXzCfVOD-UrNi86pCfTSCaFubj_Zej59U-qb34Yxv4Ca82lOg</recordid><startdate>198502</startdate><enddate>198502</enddate><creator>Norden, Carl W.</creator><creator>Shinners, Ellen</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>198502</creationdate><title>Ciprofloxacin as Therapy for Experimental Osteomyelitis Caused by Pseudomonas aeruginosa</title><author>Norden, Carl W. ; Shinners, Ellen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-812119984712bbcc1d75ad44cc88e0a7574cc9f269988edf4b0e2c357ba156f43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Animals</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobials</topic><topic>Biological and medical sciences</topic><topic>Body weight</topic><topic>Bone and Bones - analysis</topic><topic>Bones</topic><topic>Chronic Disease</topic><topic>Ciprofloxacin</topic><topic>Drug Resistance, Microbial</topic><topic>Injections</topic><topic>Inoculum</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Original Articles</topic><topic>Osteomyelitis</topic><topic>Osteomyelitis - drug therapy</topic><topic>Osteomyelitis - etiology</topic><topic>Osteomyelitis - microbiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pseudomonas aeruginosa</topic><topic>Pseudomonas aeruginosa - drug effects</topic><topic>Pseudomonas Infections - drug therapy</topic><topic>Pseudomonas Infections - microbiology</topic><topic>Quinolines - analysis</topic><topic>Quinolines - blood</topic><topic>Quinolines - pharmacology</topic><topic>Quinolines - therapeutic use</topic><topic>Rabbits</topic><topic>Sterilization</topic><topic>Tobramycin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Norden, Carl W.</creatorcontrib><creatorcontrib>Shinners, Ellen</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>The Journal of infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Norden, Carl W.</au><au>Shinners, Ellen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ciprofloxacin as Therapy for Experimental Osteomyelitis Caused by Pseudomonas aeruginosa</atitle><jtitle>The Journal of infectious diseases</jtitle><addtitle>J Infect Dis</addtitle><date>1985-02</date><risdate>1985</risdate><volume>151</volume><issue>2</issue><spage>291</spage><epage>294</epage><pages>291-294</pages><issn>0022-1899</issn><eissn>1537-6613</eissn><coden>JIDIAQ</coden><abstract>Ciprofloxacin, a new carboxyquinoline antimicrobial agent, was compared with tobramycin in the treatment of chronic osteomyelitis due to Pseudomonas aeruginosa in rabbits. Treatment with tobramycin for four weeks was ineffective (94% had positive bone cultures). In contrast, ciprofloxacin administered for four weeks sterilized the bones of all but one (94%) of 18 treated rabbits. Treatment with ciprofloxacin for two weeks was less effective than treatment for four weeks but was more effective than either treatment with tobramycin or no therapy. Two of 10 isolates from rabbits treated with ciprofloxacin for two weeks were susceptible to MICs of ciprofloxacin that were 16- and fourfold greater than the MIC for the parent strain; the other eight isolates remained sensitive to ciprofloxacin with MICs equivalent to that of the parent strain.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>3155780</pmid><doi>10.1093/infdis/151.2.291</doi><tpages>4</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-1899 |
ispartof | The Journal of infectious diseases, 1985-02, Vol.151 (2), p.291-294 |
issn | 0022-1899 1537-6613 |
language | eng |
recordid | cdi_proquest_miscellaneous_75954345 |
source | JSTOR Archival Journals and Primary Sources Collection; Oxford University Press Archive |
subjects | Animals Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobials Biological and medical sciences Body weight Bone and Bones - analysis Bones Chronic Disease Ciprofloxacin Drug Resistance, Microbial Injections Inoculum Medical sciences Medical treatment Original Articles Osteomyelitis Osteomyelitis - drug therapy Osteomyelitis - etiology Osteomyelitis - microbiology Pharmacology. Drug treatments Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology Quinolines - analysis Quinolines - blood Quinolines - pharmacology Quinolines - therapeutic use Rabbits Sterilization Tobramycin - therapeutic use |
title | Ciprofloxacin as Therapy for Experimental Osteomyelitis Caused by Pseudomonas aeruginosa |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T16%3A19%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ciprofloxacin%20as%20Therapy%20for%20Experimental%20Osteomyelitis%20Caused%20by%20Pseudomonas%20aeruginosa&rft.jtitle=The%20Journal%20of%20infectious%20diseases&rft.au=Norden,%20Carl%20W.&rft.date=1985-02&rft.volume=151&rft.issue=2&rft.spage=291&rft.epage=294&rft.pages=291-294&rft.issn=0022-1899&rft.eissn=1537-6613&rft.coden=JIDIAQ&rft_id=info:doi/10.1093/infdis/151.2.291&rft_dat=%3Cjstor_proqu%3E30109785%3C/jstor_proqu%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c346t-812119984712bbcc1d75ad44cc88e0a7574cc9f269988edf4b0e2c357ba156f43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=14085939&rft_id=info:pmid/3155780&rft_jstor_id=30109785&rfr_iscdi=true |